NCT00003190 arm group 325b3a08fdd64cda0c9ff3ea92cf21ac [clinicaltrials_resource:NCT00003190/arm-group/325b3a08fdd64cda0c9ff3ea92cf21ac]
cytarabine [clinicaltrials_resource:22446b15ce5247c9e0cf5fd2a051bad4]etoposide [clinicaltrials_resource:2e30c922aeaf033c12b0b488366729d7]daunorubicin hydrochloride [clinicaltrials_resource:ba8c3947e9272edadd939fd82459f670]Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia [clinicaltrials:NCT00003190]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00003190 arm group 325b3a08fdd64cda0c9ff3ea92cf21ac [clinicaltrials_resource:NCT00003190/arm-group/325b3a08fdd64cda0c9ff3ea92cf21ac]
Bio2RDF identifier
NCT00003190/arm-group/325b3a08fdd64cda0c9ff3ea92cf21ac
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 5b3a08fdd64cda0c9ff3ea92cf21ac
description [clinicaltrials_vocabulary:description]
Patients receive cytarabine IV ...... e IV over 2 hours on days 1-3.
identifier
clinicaltrials_resource:NCT00003190/arm-group/325b3a08fdd64cda0c9ff3ea92cf21ac
title
NCT00003190 arm group 325b3a08fdd64cda0c9ff3ea92cf21ac
@en
type
label
NCT00003190 arm group 325b3a08 ...... b3a08fdd64cda0c9ff3ea92cf21ac]
@en